AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study

Recruiting Observational Study
Coronary Heart Disease (CHD)
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
12,000 (estimated)
Sponsor
China-Japan Friendship Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Coronary artery disease remains a leading cause of global mortality. Although percutaneous coronary intervention (PCI) improves patient outcomes, the long-term risk of major adverse cardiovascular events (MACE) driven by the progression of non-target lesions (NTLs) remains substantial and continues to increase, while current risk stratification tools remain inadequate for predicting NTL progressio…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or older; 2. Scheduled for or having undergone PCI; 3. Baseline plasma sample obtainable; 4. Informed consent obtained Exclusion Criteria: 1. Pregnancy or lactation; 2. Severe hepatic or renal dysfunction; 3. Active autoimmune disease; 4. Missing critical data
Contacts

Fang Wang

+86 13683173633

wangfang@cjfh.org.cn

CONTACT